No. of Recommendations: 12
Bristol's 1 BILLION says they know something we don't. And that post must be old given the recent trial data for 214 showing clear benefit in patients who are and are not candidates for opdivo/keytruda. The poster needs to re-evaluate the newer data IMO including the INCREASING response rates with time. Also, is that poster aware of the huge number of patients that are not candidates for opdivo or keytruda?

No one said it wasn't trading at a premium... that's been discussed aplenty. NKTR is a risky investment, of that, there is no doubt. However, there IS NOT another 214 anywhere that I can find which is why the premium is there.

MC
Print the post  

Announcements

When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement